Last reviewed · How we verify
IPOL
Ipol, marketed by GlaxoSmithKline, is an established product with a key composition patent expiring in 2028. The drug's mechanism of action involves interacting with a specific target in the body to produce a desired effect, which is a core strength in its therapeutic application. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | IPOL |
|---|---|
| Also known as | Aventis Pasteur inactivated poliovirus vaccine |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Tenderness
- Swelling
- Fever (≥39°C/≥102°F)
- Pain
- Erythema
- Irritability
- Sleepiness
- Fussiness
- Crying
- Anorexia
- Vomiting
- Induration
Serious adverse events
- Anaphylactic shock
- Anaphylactic reaction
- Guillain-Barré Syndrome (GBS)
- Death
- Convulsion
- Febrile convulsion
- Syncope
- Type I hypersensitivity
- Allergic reaction
- Lymphadenopathy
Key clinical trials
- Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine (PHASE4)
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
- Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell) (PHASE3)
- A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine (PHASE3)
- A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants (PHASE3)
- Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (PHASE3)
- Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines (PHASE1)
- Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPOL CI brief — competitive landscape report
- IPOL updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI